The company acquired 26 per cent stake in SBI Cards from the GE group for Rs 2,000 crore in 2017.
Given the wider adoption of digital initiatives within the healthcare industry, Indegene plans to use the funds to accelerate its M&A (merger and acquisition) and global expansion plans
On July 1, Airtel had announced that Carlyle Group will acquire about 25 per cent stake in its data centre business, Nxtra Data, for USD 235 million
A decade after Piramal sold its domestic formulations business to Abbott Laboratories for $3.72 billion, the group is now looking at re-entering the space in India
Business Standard brings you the top headlines of the day
Carlyle Group is looking to invest up to $2 billion in Reliance Industries' retail business
The Competition Commission of India (CCI) on Wednesday said it has approved acquisition of compulsorily convertible preference shares and equity shares in Airtel's data centre business, Nxtra Data, by Carlyle Group's Comfort Investments II. The Carlyle Group in July said it will acquire about 25 per cent stake in Nxtra Data Ltd for USD 235 million (about Rs 1,780 crore). This will peg the enterprise valuation of Nxtra Data at USD 1.2 billion, which is over Rs 9,084 crore. On completion of the deal, Carlyle will hold about 25 per cent stake in the business, with Airtel continuing to hold the remaining stake of about 75 per cent. In a tweet, the regulator said it "approves proposed acquisition of compulsorily convertible preference shares & equity shares in Nxtra Data Limited @NxtraDataLtd by Comfort Investments II of Carlyle Group." Nxtra Data is a fully-owned subsidiary of Bharti Airtel Ltd and provides data centre colocation services through its 10 data centres located in India,
The company is cautious on lending to construction, gems and jewellery, hospitality and aviation sectors, says executive
The post-money enterprise valuation of Nxtra Data Ltd is approximately $1.2 billion
Here are the top headlines of the day
The transaction is subject to the necessary regulatory approvals, including approval from the Competition Commission of India
Carlyle will pick up a 20 per cent stake for $490 million or around Rs 3,700 crore in the pharma subsidiary called Piramal Pharma Ltd
US-based Carlyle Group Inc will pick up a 20% stake in Piramal Pharma for around $490 million (over Rs 3,700 crore), Piramal Enterprises said on Saturday
ZoomInfo said its customers in industries most impacted by the pandemic, including retail, restaurant, hotels, airlines and oil and gas
The transaction is being done through an equity purchase stake that values each share at Rs 86.
Unlike others of its kind, the subscription window for the IPO will remain open for 4 days, which will be from March 2 to March 5
Carlyle's decision highlights the uncertainty that the spread of the virus in China and around the world has brought to financial markets
The PE firm had acquired the stake in March from BNP Paribas for Rs 5,445 crore
The shares were offloaded at an average price of Rs 938.83, valuing the transaction at Rs 2,816.5 crore, the data showed
Move follows expiry of restrictive clauses inserted at the time he sold his stake in Metropolis Healthcare to Carlyle Group